2016
DOI: 10.3310/hta20610
|View full text |Cite
|
Sign up to set email alerts
|

Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation

Abstract: BackgroundEnd-stage renal disease is a long-term irreversible decline in kidney function requiring kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation followed by induction and maintenance immunosuppressive therapy to reduce the risk of kidney rejection and prolong graft survival.ObjectivesTo systematically review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect,®Novartis Pharmaceuticals) and ra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
11
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(11 citation statements)
references
References 261 publications
0
11
0
Order By: Relevance
“…Graft rejection is a common complication in kidney transplant patients [ 33 ]. As transplantation is still the most promising therapeutic option for patients with end-stage renal diseases [ 3 ], risk adapted immunomodulatory therapy is one of the key points for successful transplantation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Graft rejection is a common complication in kidney transplant patients [ 33 ]. As transplantation is still the most promising therapeutic option for patients with end-stage renal diseases [ 3 ], risk adapted immunomodulatory therapy is one of the key points for successful transplantation.…”
Section: Discussionmentioning
confidence: 99%
“…Since T-cell migration into the graft and their infiltration is essential for T-cell-mediated rejection and our study indicates that AQP3 expression is required for T-cell migration, blockade of AQP3 might depict a novel and promising therapeutic strategy to inhibit T-cell migration and could be a promising prophylactic therapy in transplantation. To date, steroids, calcineurin inhibitors, inosine-5′-monophosphate dehydrogenase inhibitors, or mTOR inhibitors are routinely applied in immune suppressive therapy [ 33 ]. However, application of these immune suppressive drugs is associated with a higher risk of infection or even cancer [ 43 , 44 ].…”
Section: Discussionmentioning
confidence: 99%
“…It is associated with cytokine release syndrome, thrombocytopenia, lymphopenia and other conditions [17]. Compared with ATG, IL-2R antibodies, with a low prevalence of side effects, tend to be increasingly recommended for low or average immunologic risk patients [17][18][19]. However, in the USA transplant centers, T-cell depleting agents (including ATG/ALG and alemtuzumab) were preferred regardless of immunologic risk judged by calculated penal reactive antibody [16,20].…”
Section: Discussionmentioning
confidence: 99%
“…This may provide a better prognosis for clinical outcomes and improve the quality of life with decreasing medical costs (21, 22). …”
Section: Biomarkers After Organ Transplantation and Risk Managementmentioning
confidence: 99%
“…Risk management of organ transplant recipients requires the use of the early biomarkers of acute or chronic kidney and liver injury as well. This may provide a better prognosis for clinical outcomes and improve the quality of life with decreasing medical costs ( 21 , 22 ).…”
Section: Biomarkers After Organ Transplantation and Risk Managementmentioning
confidence: 99%